KR20150013232A - 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 옥시스테롤 유사체 oxy133 - Google Patents

골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 옥시스테롤 유사체 oxy133 Download PDF

Info

Publication number
KR20150013232A
KR20150013232A KR1020147033925A KR20147033925A KR20150013232A KR 20150013232 A KR20150013232 A KR 20150013232A KR 1020147033925 A KR1020147033925 A KR 1020147033925A KR 20147033925 A KR20147033925 A KR 20147033925A KR 20150013232 A KR20150013232 A KR 20150013232A
Authority
KR
South Korea
Prior art keywords
oxy133
bone
subject
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147033925A
Other languages
English (en)
Korean (ko)
Inventor
파하드 파하미
마이클 이. 정
프랭크 스타펜벡
Original Assignee
더 리전트 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리전트 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리전트 오브 더 유니버시티 오브 캘리포니아
Publication of KR20150013232A publication Critical patent/KR20150013232A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147033925A 2012-05-07 2013-03-15 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 옥시스테롤 유사체 oxy133 Ceased KR20150013232A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643746P 2012-05-07 2012-05-07
US61/643,746 2012-05-07
PCT/US2013/032693 WO2013169399A1 (en) 2012-05-07 2013-03-15 Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis

Publications (1)

Publication Number Publication Date
KR20150013232A true KR20150013232A (ko) 2015-02-04

Family

ID=49551140

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147033925A Ceased KR20150013232A (ko) 2012-05-07 2013-03-15 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 옥시스테롤 유사체 oxy133

Country Status (10)

Country Link
US (1) US9717742B2 (enExample)
EP (1) EP2847206A4 (enExample)
JP (1) JP6262723B2 (enExample)
KR (1) KR20150013232A (enExample)
CN (1) CN104395331B (enExample)
AU (1) AU2013260059B2 (enExample)
CA (1) CA2872751A1 (enExample)
IN (1) IN2014DN09805A (enExample)
RU (1) RU2632191C2 (enExample)
WO (1) WO2013169399A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102283508B1 (ko) * 2020-04-17 2021-07-29 가톨릭대학교 산학협력단 골형성 단백질-2를 유효성분으로 포함하는 줄기세포 스페로이드의 골분화 촉진용 조성물

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
WO2007098281A2 (en) 2006-02-27 2007-08-30 Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
AU2008331808B2 (en) 2007-03-16 2014-08-21 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
RU2632191C2 (ru) 2012-05-07 2017-10-03 Те Риджентс Оф Те Юниверсити Оф Калифорния Аналог оксистерола oxy133 индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез
CA2911205A1 (en) * 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
CN106232612B (zh) * 2014-05-02 2019-01-29 加利福尼亚大学董事会 骨选择性成骨性氧固醇双膦酸盐类似物
US9657052B2 (en) * 2014-12-09 2017-05-23 Warsaw Orthopedic, Inc. Compounds and methods of making sterols using diols
US20180133211A1 (en) * 2015-05-19 2018-05-17 Mayo Foundation For Medical Education And Research Methods and materials for promoting bone formation
US9877836B2 (en) * 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
US9878070B2 (en) 2015-06-17 2018-01-30 Warsaw Orthopedic, Inc. Malleable implants including an oxysterol and methods of use
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
EP3310337B1 (en) * 2015-06-17 2021-03-03 Warsaw Orthopedic, Inc. Implants including an oxysterol and methods of use
US12171909B2 (en) * 2015-07-10 2024-12-24 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
AU2016347052B2 (en) * 2015-10-27 2021-03-25 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
US11090411B2 (en) 2016-01-28 2021-08-17 Warsaw Orthopedic, Inc. Electron beam irradiated osteoinductive bone implant
US9987290B2 (en) 2016-03-28 2018-06-05 Warsaw Orthopedic, Inc. Methods for the separation and detection of an oxysterol
US20170275330A1 (en) * 2016-03-28 2017-09-28 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
CN105924493A (zh) * 2016-04-23 2016-09-07 何华琼 盐酸布桂嗪的药物组合物及其在生物医药中的应用
US10688222B2 (en) * 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US10294264B2 (en) 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) * 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
WO2019048898A1 (en) 2017-09-05 2019-03-14 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB869007A (en) 1956-10-03 1961-05-25 Ciba Ltd New heterocyclically substituted steroids
CH433275A (de) 1963-07-09 1967-04-15 Hoffmann La Roche Verfahren zur Herstellung von 19-Alkylsteroiden
JPS5111114B1 (enExample) 1969-03-14 1976-04-08
US3887545A (en) 1973-11-12 1975-06-03 Hoffmann La Roche Synthesis of 1{60 -hydroxylated cholesterol derivatives
US4264512A (en) 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4743597A (en) 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
LU87201A1 (fr) 1988-04-14 1989-11-14 Cird Complexes a base d'anthraline et d'un sterol,leur procede d'obtention et leur utilisation en therapeutique et cosmetique
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
GB9118465D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US7060450B1 (en) 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
DE69519368T2 (de) 1994-01-06 2001-03-08 Sri International, Menlo Park Neue antiandrogenen mitteln pharmazeutische präparate und verwendungen davon
CA2250874A1 (en) 1996-04-09 1997-10-16 Btg International Limited Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
ATE439849T1 (de) 1996-04-19 2009-09-15 Osiris Therapeutics Inc Die wiederherstellung und verstärkung von knochen mittels mesenchymalen stammzellen
US6893830B1 (en) 1996-09-27 2005-05-17 The Board Of Regents Of The University Of Texas System Method of screening oxysterol activation of LXRα
US5840752A (en) 1996-11-21 1998-11-24 Henry; James P. Reduction of hair growth
US6080779A (en) 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
PL334840A1 (en) 1997-01-24 2000-03-27 Univ California Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation
DE69809905T2 (de) 1997-05-16 2003-08-28 Akzo Nobel N.V., Arnheim/Arnhem 20-aralkyl-5,alpha,-pregnan derivate
DE19723794A1 (de) 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US5929062A (en) 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
AU8173098A (en) 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
JP2002506030A (ja) 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 骨再吸収の阻害方法
EP0943332A1 (en) 1998-03-19 1999-09-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Prevention and treatment of adhesions
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
AU3285000A (en) 1999-03-09 2000-09-28 Akzo Nobel N.V. 22r-hydroxycholesta-8,14-diene derivatives for the inhibition of meiosis
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6586189B2 (en) 1999-06-18 2003-07-01 City Of Hope Screening method for PPAR-γ ligands
AU1291901A (en) 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
GB0101933D0 (en) 2001-01-25 2001-03-07 Astrazeneca Ab Therapy
JP4866534B2 (ja) 2001-02-12 2012-02-01 エーエスエム アメリカ インコーポレイテッド 半導体膜の改良された堆積方法
JP2004534743A (ja) 2001-04-09 2004-11-18 ロランティス リミテッド ヘッジホッグ
CN100430062C (zh) 2002-03-15 2008-11-05 萨马里坦药品公司 神经保护性螺甾烯醇药用组合物
CA2495882A1 (en) 2002-08-29 2004-03-11 The Regents Of The University Of California Agents and methods for enhancing bone formation
DE10307104A1 (de) 2003-02-19 2004-09-23 Schering Ag Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate
AU2004255285A1 (en) 2003-07-09 2005-01-20 Forbes Medi-Tech Inc Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
WO2005028616A2 (en) 2003-07-24 2005-03-31 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and methods of use thereof to treat heart disorders
EP1697413A2 (en) 2003-08-18 2006-09-06 Wyeth Human lxr alpha variants
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US7196220B2 (en) 2003-12-24 2007-03-27 University Of Louisville Research Foundation, Inc. Bone targeting compounds for delivering agents to the bone for interaction therewith
WO2005123757A1 (en) 2004-06-10 2005-12-29 Merck & Co., Inc. Estrogen receptor modulators
CA2575878A1 (en) 2004-08-02 2006-02-09 Novozymes A/S Creation of diversity in polypeptides
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
US20090202660A1 (en) 2005-04-07 2009-08-13 The Regents Of The University Of California Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation
US20090220562A1 (en) 2005-09-02 2009-09-03 Farhad Parhami Osteogenic and anti-adipogenic oxysterols
WO2007098281A2 (en) 2006-02-27 2007-08-30 Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
US20100048944A1 (en) 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
WO2008036238A2 (en) 2006-09-19 2008-03-27 Wyeth Use of lxr modulators for the prevention and treatment of skin aging
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
EP2111225A4 (en) 2006-12-19 2010-02-10 Univ California INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLE
WO2008103951A1 (en) 2007-02-23 2008-08-28 University Of Louisville Research Foundation, Inc Methods and compounds for the targeted delivery of agents to bone for interaction therewith
WO2008109780A1 (en) 2007-03-06 2008-09-12 University Of Louisville Research Foundation, Inc Methods and compounds for the targeted delivery of agents to bone for interaction therewith
AU2008331808B2 (en) * 2007-03-16 2014-08-21 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
US20100112030A1 (en) 2007-03-16 2010-05-06 The Regents Of The University Of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
MY163799A (en) 2008-02-07 2017-10-24 Dsg Tech Holdings Limited Method of making an absorbent composite and absorbent articles employing the same
WO2011006087A1 (en) 2009-07-10 2011-01-13 The Regents Of The University Of California Inhibition of ppar gamma expression in preadipocyte cells by oxysterols
WO2011103175A2 (en) 2010-02-16 2011-08-25 The Regents Of The University Of California Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
WO2012024583A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024581A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024584A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
CN104507951B (zh) 2012-05-07 2016-09-07 加利福尼亚大学董事会 诱导骨生成和hedgehog信号传导且抑制脂肪形成的氧固醇类似物氧固醇化合物149
RU2632191C2 (ru) 2012-05-07 2017-10-03 Те Риджентс Оф Те Юниверсити Оф Калифорния Аналог оксистерола oxy133 индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез
CA2911205A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
CN106232612B (zh) 2014-05-02 2019-01-29 加利福尼亚大学董事会 骨选择性成骨性氧固醇双膦酸盐类似物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102283508B1 (ko) * 2020-04-17 2021-07-29 가톨릭대학교 산학협력단 골형성 단백질-2를 유효성분으로 포함하는 줄기세포 스페로이드의 골분화 촉진용 조성물

Also Published As

Publication number Publication date
IN2014DN09805A (enExample) 2015-07-31
AU2013260059A1 (en) 2014-11-27
JP2015518493A (ja) 2015-07-02
CN104395331B (zh) 2016-11-02
CN104395331A (zh) 2015-03-04
HK1207649A1 (en) 2016-02-05
EP2847206A4 (en) 2016-01-20
EP2847206A1 (en) 2015-03-18
US9717742B2 (en) 2017-08-01
AU2013260059B2 (en) 2017-05-18
RU2014149164A (ru) 2016-07-10
JP6262723B2 (ja) 2018-01-17
US20150118277A1 (en) 2015-04-30
WO2013169399A1 (en) 2013-11-14
CA2872751A1 (en) 2013-11-14
RU2632191C2 (ru) 2017-10-03

Similar Documents

Publication Publication Date Title
KR20150013232A (ko) 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 옥시스테롤 유사체 oxy133
KR20150008160A (ko) 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 신규 옥시스테롤 유사체 oxy149
Siddiqui et al. Physiological bone remodeling: systemic regulation and growth factor involvement
Johnson et al. Novel oxysterols have pro‐osteogenic and anti‐adipogenic effects in vitro and induce spinal fusion in vivo
Khorsand et al. Regeneration of bone using nanoplex delivery of FGF-2 and BMP-2 genes in diaphyseal long bone radial defects in a diabetic rabbit model
Fu et al. Effect of 1, 25-dihydroxy vitamin D3 on fracture healing and bone remodeling in ovariectomized rat femora
JP2009528291A (ja) オキシステロール化合物及びヘッジホッグ経路
KR101018050B1 (ko) 골형성촉진용 합성펩타이드 ｂｆｐ1, 상기 합성 펩타이드 ｂｆｐ1을 포함하는 골형성촉진기능성 약학조성물 및 배지조성물
JP2016517888A (ja) 骨選択的骨形成のオキシステロール骨標的薬剤
Feng et al. Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats
CN112263717A (zh) 具有氧化固醇药物负载的植入物和使用方法
WO2012024584A2 (en) Oxysterol compounds
KR20090132506A (ko) 골형성촉진용 합성펩타이드, 상기 합성 펩타이드를 포함하는 약학조성물 및 배지조성물
Sartoretto et al. The role of apoptosis associated speck-like protein containing a caspase-1 recruitment domain (ASC) in response to bone substitutes
US20190336575A1 (en) Reversing deficient hedgehog signaling restores deficient skeletal regeneration
Li et al. Pharmacological inhibition of DKK1 promotes spine fusion in an ovariectomized rat model
KR20180102154A (ko) Llp2a-비스포스포네이트 화합물로 뼈괴사를 치료하는 방법
HK1207649B (en) Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
Zhang et al. Determination of a critical size calvarial defect in senile osteoporotic mice model based on in vivo micro-computed tomography and histological evaluation
JP2009298784A (ja) 骨形成促進用合成ペプチド、この合成ペプチドを含む薬学組成物および培地組成物
HK1208871B (en) Oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
Setiawan et al. The Therapeutic Potentials of Intermittent Hypoxia on Bone Healing: A Systematic Review
Aita A Novel Mouse Model for the Study of Spinal Cord Injuryassociated Heterotopic Ossification
JP2024509346A (ja) 骨疾患を治療するための二糖類
Peters et al. Translational Research in Anatomy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180314

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190418

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190622

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190418

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I